At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Apr 1, 2026 at 07:00 ET
Ocular Therapeutix announced upcoming presentations of Phase 3 data for its investigational therapy AXPAXLI™ (OTX-TKI) in wet AMD at major ophthalmology conferences in April 2026. The data disclosures are part of ongoing scientific dissemination, not a regulatory approval or clinical trial result announcement.
- Ocular Therapeutix will present SOL-1 Phase 3 data for AXPAXLI™ (OTX-TKI) in wet AMD at the Vit-Buckle Society meeting on April 11, 2026.
- Additional presentations on diabetic retinal disease and wet AMD will occur at CNO 2026 in Buenos Aires from April 15–17, 2026.
- AXPAXLI™ is an axitinib intravitreal hydrogel in Phase 3 trials for wet AMD and diabetic retinal disease, including NPDR.
- No new clinical data, FDA decision, or commercial update was released, this is a schedule of upcoming scientific presentations.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access